Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1901)
Drug Name
BNP-1350
Synonyms
Cositecan; Cositecan (USAN); Cositecan [USAN:INN]; Karenitecin; Karenitecin (TN); POADTFBBIXOWFJ-VWLOTQADSA-N; SCHEMBL2315201; Z-3161; ZINC169746728; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-(2-trimethylsilyl)ethyl)-, (4S)-; 203923-89-1; 24R60NVC41; 7-Trimethylsilylethylcamptothecin; 923K891; AC1L3WN8; AN-29989; BNP 1350; BNP-1350; BNP1350; CHEMBL1997373; CS-0003573; D09327; DB 172; DB05806; DTXSID90174340; HY-14812; NCI60_038797; NSC-710270; NSC710270; UNII-24R60NVC41
Indication Ovarian cancer [ICD11: 2C73] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 448.6 Topological Polar Surface Area 79.7
Heavy Atom Count 32 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
148202
PubChem SID
530668 ; 10249845 ; 11443149 ; 14906395 ; 46225149 ; 50873155 ; 57346730 ; 96026007 ; 104418481 ; 126681210 ; 135105770 ; 140587255 ; 172918703 ; 175427037 ; 184826536 ; 198949673 ; 223663599 ; 228436255 ; 241051100 ; 242534801 ; 246301288 ; 252215634
CAS Number
203923-89-1
TTD Drug ID
D02CZK
Formula
C25H28N2O4Si
Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O
InChI
1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1
InChIKey
POADTFBBIXOWFJ-VWLOTQADSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Unclear DM009999 N. A. Unclear 1 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000396 BNP-1350 . Unclear CYP3A4 ... [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 ClinicalTrials.gov (NCT00477282) Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer.
2 Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development. J Clin Pharmacol. 2003 Sep;43(9):1008-14.
3 U. S. FDA Label -BNP-1350

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.